 |
        |
Joyce Tsang, Ph.D.Board Member Dr. Tsang joined the ORTHOCON® Board of Directors in 2009 and represents ProQuest’s investment in the company. She currently is a General Partner at ProQuest Investments. Prior to joining ProQuest, Dr. Tsang held positions with McKinsey & Company and Smith Barney (now Citi Smith Barney). At McKinsey, she advised a variety of healthcare-focused Fortune 500 clients on strategic, operational, and organizational issues. At Smith Barney, Dr. Tsang worked on structuring numerous debt and equity offerings. Dr. Tsang received an A.B. in molecular biology from Princeton University, where she graduated cum laude. She received a Ph.D. in the macromolecular and cellular structure and chemistry from The Scripps Research Institute. Return to Leadership |
 |
||||||
 |
 |
ORTHOCON® estimates that over 3.5 million patients undergoing surgeries in the United States and Europe each year could benefit from the intraoperative use of HEMASORB.
 |
|
ORTHOCON® Names David J. Hart Vice President of Business Operations
March 15, 2012 - Click to Download Canaan Partners Closes $600 Million Fund, Canaan IX January 9, 2012 - Click to Read More |
||
|
||||||
